SS
DMRA

SBI Securities’s Damora Therapeutics DMRA Stock Holding History

SBI Securities’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$364 Hold
14
– – ﹤0.01% 3147
2026
Q1 		$363 Hold
14
– – ﹤0.01% 3008
2025
Q4 		$322 Sell
14
-4
-22% -$70 ﹤0.01% 3040
2025
Q3 		$67 Hold
18
– – ﹤0.01% 3630
2025
Q2 		$61 Hold
18
– – ﹤0.01% 3676
2025
Q1 		$56 Hold
18
– – ﹤0.01% 3615
2024
Q4 		$84 Buy
+18
New +$118 ﹤0.01% 3507

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

SBI Securities's DMRA Position: Q2 2026 in Review

SBI Securities held its Damora Therapeutics (DMRA) position steady in Q2 2026 at 14 shares worth $364. The position accounts for ﹤0.01% of the portfolio, ranked #3147.

SBI Securities first reported a position in DMRA in Q4 2024 and has held it in 7 quarters since. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • SBI Securities held 14 shares of Damora Therapeutics worth $364 as of Q2 2026.
  • SBI Securities left its Damora Therapeutics share count unchanged in Q2 2026.
  • Damora Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3147 holding.
  • SBI Securities first reported a position in Damora Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.